Emerging topical drugs for the treatment of rosacea. (2nd January 2021)

• Record Type: Journal Article
• Authors: Dall'Oglio, Federica; Nasca, Maria Rita; Micali, Giuseppe
• Is Part Of: Expert opinion on emerging drugs. Volume 26:Number 1(2021)
• Page Start: 27
• Page End: 38
• Publication Date: 2021-01-02
• Subjects: Emerging drugs -- mechanism-based treatment -- new treatments -- pharmacotherapy -- rosacea -- topical treatment; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2021.1887138
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction : Rosacea is a common, chronic and relapsing inflammatory skin disease of the centrofacial area. Despite advancing knowledge on its pathogenesis, diagnosis, and treatment, some major unknowns still remain, including systematic evidence-based guidelines useful both for clinical assessment and therapeutic management. Topical treatment is regarded as a first-line option for mild to moderate rosacea and includes traditional and new FDA-approved prescription drugs, as well as off-label alternative topical agents. Areas covered : Since improved awareness of rosacea pathogenetic mechanisms has led to the development of new potential therapeutic agents, a search was performed on the ClinicalTrial.gov registry. The results identified several investigational topical drugs able to target one or more of the pathogenetic factors of rosacea. Expert opinion : The main unmet needs in the topical treatment of rosacea remain the management of vasomotor flushes and telangiectasias, as well as of troublesome symptoms such as burning and/or stinging. No single agent effective on all rosacea phenotypes is available so far, and preventive treatments capable of halting disease progression have not been identified yet. Finally, data on long-term efficacy and tolerability are still incomplete, especially for drugs more recently introduced in the market.